Article Text

Download PDFPDF

Antibodies to intermediate filaments in polymyalgia rheumatica and giant cell arteritis: a sequential study.
  1. B Dasgupta,
  2. O Duke,
  3. V Kyle,
  4. D G Macfarlane,
  5. B L Hazleman,
  6. G S Panayi
  1. Rheumatology Unit, UMDS, Guy's Hospital, London.


    Serum specimens from 35 patients with polymyalgia rheumatica and giant cell arteritis (PMR/GCA) were obtained sequentially at variable time intervals up to a year from onset of disease. These were tested for antibodies to intermediate filaments by indirect immunofluorescence using HEp2 cells as substrate. Twenty four of 35 (68%) patients' sera at onset of disease were positive at an anti-intermediate filament antibody (AIFA) titre of greater than 1/40 compared with three outs of 19 (15%) control sera. AIFA were predominantly of IgM class, and there was no significant change in AIFA titres on follow up despite clinical remission of disease.

    Statistics from

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.